The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E2 secretion by cultured human adult microglia: Implications for Alzheimer's disease

Brain Research

Volumn 951, Issue 2, 2002, Pages 218-226

  Hoozemans, Jeroen J M ^a   Veerhuis, Robert ^a   Janssen, Ingrid ^a   Van Elk, Evert Jan ^a   Rozemuller, Annemieke J M ^b   Eikelenboom, Piet ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Arachidonic acid; Cyclooxygenase 1; Cyclooxygenase 2; Microglia; Prostaglandin E2

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; AMYLOID BETA PROTEIN; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DRUG INHIBITION; DRUG SELECTIVITY; ELECTRIC POTENTIAL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; MICROGLIA; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REDUCTION; STIMULATION; TISSUE CULTURE;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ARACHIDONIC ACID; BRAIN; CELLS, CULTURED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYTOKINES; DINOPROSTONE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LIPOPOLYSACCHARIDES; MEMBRANE PROTEINS; MICROGLIA; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SENILE PLAQUES;

EID: 0037019859     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03164-5     Document Type: Article

References (35)

1. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 47:1996;425-432.
2. Lucca U. Nonsteroidal anti-inflammatory drugs and Alzheimer's: Update on recent data and their therapeutical implications. CNS Drugs. 11:1999;207-224.
3. Vane J.R., Botting R.M. Anti-inflammatory drugs and their mechanism of action. Inflamm. Res. 47:1998;S78-S87.
4. Vane J.R., Bakhle Y.S., Botting R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38:1998;97-120.
5. Willard L.B., Hauss-Wegrzyniak B., Danysz W., Wenk G.L. The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp. Brain Res. 134:2000;58-65.
6. Blom M.A., van Twillert M.G., de Vries S.C., Engels F., Finch C.E., Veerhuis R., Eikelenboom P. NSAIDS inhibit the IL-1 beta-induced IL-6 release from human post-mortem astrocytes: the involvement of prostaglandin E2. Brain Res. 777:1997;210-218.
7. Fiebich B.L., Hull M., Lieb K., Gyufko K., Berger M., Bauer J. Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells. J. Neurochem. 68:1997;704-709.
8. Lee R.K., Knapp S., Wurtman R.J. Prostaglandin E2 stimulates amyloid precursor protein gene expression: inhibition by immunosuppressants. J. Neurosci. 19:1999;940-947.
9. Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W., Zalinski J., Cofield M., Mansukhani L., Willson P. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
10. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K.H., Frautschy S.A., Cole G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20:2000;5709-5714.
11. Hauss-Wegrzyniak B., Dobrzanski P., Stoehr J.D., Wenk G.L. Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease. Brain Res. 780:1998;294-303.
12. De Groot C.J., Montagne L., Janssen I., Ravid R., van der Valk P., Veerhuis R. Isolation and characterisation of adult microglial cells and oligodendrocytes derived from postmortem human brain tissue. Brain Res. Protoc. 5:2000;85-94.
13. Obrig T.G., Culp W.J., McKeehan W.L., Hardesty B. The mechanism by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes. J. Biol. Chem. 246:1971;174-181.
14. Griffin W.S., Sheng J.G., Roberts G.W., Mrak R.E. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54:1995;276-281.
15. Bauer J., Strauss S., Schreiter-Gasser U., Ganter U., Schlegel P., Witt I., Yolk B., Berger M. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 285:1991;111-114.
16. Fillit H., Ding W.H., Buee L., Kalman J., Altstiel L., Lawlor B., Wolf-Klein G. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 129:1991;318-320.
17. Blum-Degen D., Muller T., Kuhn W., Gerlach M., Przuntek H., Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202:1995;17-20.
18. Cacabelos R., Barquero M., Garcia P., Alvarez X.A., Varela D.S. Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders. Methods Find. Exp. Clin. Pharmacol. 13:1991;455-458.
19. Tarkowski E., Blennow K., Wallin A., Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J. Clin. Immunol. 19:1999;223-230.
20. Bauer M.K., Lieb K., Schulze-Osthoff K., Berger M., Gebicke-Haerter P.J., Bauer J., Fiebich B.L. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur. J. Biochem. 243:1997;726-731.
21. Minghetti L., Levi G. Induction of prostanoid biosynthesis by bacterial lipopolysaccharide and isoproterenol in rat microglial cultures. J. Neurochem. 65:1995;2690-2698.
22. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., van Muiswinkel M.F., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging. 21:2000;383-421.
23. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res. 830:1999;226-236.
24. Yermakova A.V., Rollins J., Callahan L.M., Rogers J., O'Banion M.K. Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J. Neuropathol. Exp. Neurol. 58:1999;1135-1146.
25. Hoozemans J.J., Rozemuller A.J., Janssen I., De Groot C.J., Veerhuis R., Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol. (Berl.). 101:2001;2-8.
26. Pasinetti G.M., Aisen P.S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience. 87:1998;319-324.
27. S.M. Sainali, D.M. Ingram, S. Talwker, Results of a double-blind, placebo-controlled study of Celecoxib in the treatment of progression of Alzheimer's disease (abstract), in: Sixth International Stockholm-Springfield Symposium of Advances in Alzheimer Therapy, April 5-8, Stockholm, 2000.
28. Smith C.J., Zhang Y., Koboldt C.M., Muhammad J., Zweifel B.S., Shaffer A., Talley J.J., Masferrer J.L., Seibert K., Isakson P.C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. USA. 95:1998;13313-13318.
29. Meade E.A., Smith W.L., DeWitt D.L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 268:1993;6610-6614.
30. Anderson G.D., Hauser S.D., McGarity K.L., Bremer M.E., Isakson P.C., Gregory S.A. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J. Clin. Invest. 97:1996;2672-2679.
31. Portanova J.P., Zhang Y., Anderson G.D., Hauser S.D., Masferrer J.L., Seibert K., Gregory S.A., Isakson P.C. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J. Exp. Med. 184:1996;883-891.
32. Langenbach R., Morham S.G., Tiano H.F., Loftin C.D., Ghanayem B.I., Chulada P.C., Mahler J.F., Lee C.A., Goulding E.H., Kluckman K.D. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 83:1995;483-492.
33. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272:1997;3406-3410.
34. Gierse J.K., McDonald J.J., Hauser S.D., Rangwala S.H., Koboldt C.M., Seibert K. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J. Biol. Chem. 271:1996;15810-15814.
35. Johnson J.L., Wimsatt J., Buckel S.D., Dyer R.D., Maddipati K.R. Purification and characterization of prostaglandin H synthase-2 from sheep placental cotyledons. Arch. Biochem. Biophys. 324:1995;26-34.